Clinical trial participation improves survival outcomes by increasing availability of new therapeutic agents in multiple myeloma

Br J Haematol. 2022 Feb;196(4):1117-1120. doi: 10.1111/bjh.17898. Epub 2021 Oct 20.

Authors

Sung-Hoon Jung¹, Je-Jung Lee¹, Ga-Young Song¹, Ho Sup Lee², Seok Jin Kim³, Sang Eun Yoon³, Kihyun Kim³

Affiliations

¹ Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo, Republic of Korea.
² Kosin University Gospel Hospital, Busan, Republic of Korea.
³ Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea.

PMID: 34671972
DOI: 10.1111/bjh.17898

No abstract available

Keywords: clinical trial; multiple myeloma; survival.

Publication types

Letter

MeSH terms

Aged
Dexamethasone / pharmacology
Dexamethasone / therapeutic use*
Female
Humans
Male
Multiple Myeloma / drug therapy*
Multiple Myeloma / mortality
Retrospective Studies
Survival Analysis

Substances

Dexamethasone